Weight loss in patients taking felbamate

D. C. Bergen, R. K. Ristanovic, K. Waicosky, Andres M Kanner, T. J. Hoeppner

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Felbamate is a new antiepileptic drug (AED) with a good safety profile. Anorexia has been reported in patients taking felbamate, but the incidence and severity of this side effect have not been adequately investigated. We studied 65 patients with intractable seizures who received adjunctive felbamate therapy as part of clinical research trials or in a compassionate- use program. Mean treatment time on felbamate was 23 weeks (±SD 16; range, 6-116 weeks). Forty-nine patients (75%) lost weight during the trials. For subjects older than 15 years, there was a mean weight loss of 3.17 kg or 4.11% of body weight (T = 191.5, z = 4.18, p < 0.001). For subjects 15 years or younger, there was a mean weight loss of 0.20 kg or a loss of 1.77% of body weight (T = 52.5, NS). Twenty-two patients (34%) lost >4 kg, and seven patients (11%) lost >8 kg. Adjunctive treatment of adults with severe epilepsy with felbamate may be associated with clinically significant weight loss.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalClinical Neuropharmacology
Volume18
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

felbamate
Weight Loss
Compassionate Use Trials
Anorexia
Anticonvulsants
Epilepsy
Seizures
Therapeutics
Body Weight
Clinical Trials
Safety
Weights and Measures

Keywords

  • Anorexia
  • Epilepsy
  • Felbamate
  • Weight loss

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bergen, D. C., Ristanovic, R. K., Waicosky, K., Kanner, A. M., & Hoeppner, T. J. (1995). Weight loss in patients taking felbamate. Clinical Neuropharmacology, 18(1), 23-27.

Weight loss in patients taking felbamate. / Bergen, D. C.; Ristanovic, R. K.; Waicosky, K.; Kanner, Andres M; Hoeppner, T. J.

In: Clinical Neuropharmacology, Vol. 18, No. 1, 1995, p. 23-27.

Research output: Contribution to journalArticle

Bergen, DC, Ristanovic, RK, Waicosky, K, Kanner, AM & Hoeppner, TJ 1995, 'Weight loss in patients taking felbamate', Clinical Neuropharmacology, vol. 18, no. 1, pp. 23-27.
Bergen DC, Ristanovic RK, Waicosky K, Kanner AM, Hoeppner TJ. Weight loss in patients taking felbamate. Clinical Neuropharmacology. 1995;18(1):23-27.
Bergen, D. C. ; Ristanovic, R. K. ; Waicosky, K. ; Kanner, Andres M ; Hoeppner, T. J. / Weight loss in patients taking felbamate. In: Clinical Neuropharmacology. 1995 ; Vol. 18, No. 1. pp. 23-27.
@article{49fd295af60744b79e6a184f6037c27a,
title = "Weight loss in patients taking felbamate",
abstract = "Felbamate is a new antiepileptic drug (AED) with a good safety profile. Anorexia has been reported in patients taking felbamate, but the incidence and severity of this side effect have not been adequately investigated. We studied 65 patients with intractable seizures who received adjunctive felbamate therapy as part of clinical research trials or in a compassionate- use program. Mean treatment time on felbamate was 23 weeks (±SD 16; range, 6-116 weeks). Forty-nine patients (75{\%}) lost weight during the trials. For subjects older than 15 years, there was a mean weight loss of 3.17 kg or 4.11{\%} of body weight (T = 191.5, z = 4.18, p < 0.001). For subjects 15 years or younger, there was a mean weight loss of 0.20 kg or a loss of 1.77{\%} of body weight (T = 52.5, NS). Twenty-two patients (34{\%}) lost >4 kg, and seven patients (11{\%}) lost >8 kg. Adjunctive treatment of adults with severe epilepsy with felbamate may be associated with clinically significant weight loss.",
keywords = "Anorexia, Epilepsy, Felbamate, Weight loss",
author = "Bergen, {D. C.} and Ristanovic, {R. K.} and K. Waicosky and Kanner, {Andres M} and Hoeppner, {T. J.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "23--27",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Weight loss in patients taking felbamate

AU - Bergen, D. C.

AU - Ristanovic, R. K.

AU - Waicosky, K.

AU - Kanner, Andres M

AU - Hoeppner, T. J.

PY - 1995

Y1 - 1995

N2 - Felbamate is a new antiepileptic drug (AED) with a good safety profile. Anorexia has been reported in patients taking felbamate, but the incidence and severity of this side effect have not been adequately investigated. We studied 65 patients with intractable seizures who received adjunctive felbamate therapy as part of clinical research trials or in a compassionate- use program. Mean treatment time on felbamate was 23 weeks (±SD 16; range, 6-116 weeks). Forty-nine patients (75%) lost weight during the trials. For subjects older than 15 years, there was a mean weight loss of 3.17 kg or 4.11% of body weight (T = 191.5, z = 4.18, p < 0.001). For subjects 15 years or younger, there was a mean weight loss of 0.20 kg or a loss of 1.77% of body weight (T = 52.5, NS). Twenty-two patients (34%) lost >4 kg, and seven patients (11%) lost >8 kg. Adjunctive treatment of adults with severe epilepsy with felbamate may be associated with clinically significant weight loss.

AB - Felbamate is a new antiepileptic drug (AED) with a good safety profile. Anorexia has been reported in patients taking felbamate, but the incidence and severity of this side effect have not been adequately investigated. We studied 65 patients with intractable seizures who received adjunctive felbamate therapy as part of clinical research trials or in a compassionate- use program. Mean treatment time on felbamate was 23 weeks (±SD 16; range, 6-116 weeks). Forty-nine patients (75%) lost weight during the trials. For subjects older than 15 years, there was a mean weight loss of 3.17 kg or 4.11% of body weight (T = 191.5, z = 4.18, p < 0.001). For subjects 15 years or younger, there was a mean weight loss of 0.20 kg or a loss of 1.77% of body weight (T = 52.5, NS). Twenty-two patients (34%) lost >4 kg, and seven patients (11%) lost >8 kg. Adjunctive treatment of adults with severe epilepsy with felbamate may be associated with clinically significant weight loss.

KW - Anorexia

KW - Epilepsy

KW - Felbamate

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=0028854393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028854393&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 23

EP - 27

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -